Amgen researchers confirm the lackluster data on the KRAS G12C drug AMG 510 reported at ESMO — but they still have a long way to go exploring options
We learned at ESMO that Amgen’s star cancer drug, the pioneering KRAS G12C player AMG 510, tended toward the unimpressive when applied outside non …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
